Clinical Trial Update: Safety And Efficacy Study Of CP-675,206 In HIV-Infected Patients [Phase 2]

View source ↗

Summary

The Phase 2 safety and efficacy study of CP-675,206 in HIV-infected patients has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• CP-675,206

Snippet

Sponsor: Pfizer | Conditions: Human Immunodeficiency Virus | Phase 2 | Status: WITHDRAWN